http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock targets 2026 apitegromab BLA resubmission and launch
-
Scholar Rock Highlights 2026 Strategic Priorities
-
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Present at Upcoming Investor Conferences
-
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
-
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
FDA rejects Scholar Rock's apitegromab application due to facility issues
-
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish F
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
-
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
-
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
-
Scholar Rock Holding (SRRK) Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) Appoints as Rebecca McLeod Chief Brand Officer and U.S. General Manager
-
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
-
Scholar Rock to Present at the Jefferies Global Healthcare Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
-
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Holding Corp. (SRRK) Appoints David L. Hallal as CEO
-
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Holding Corp. (SRRK): FDA Grants Priority Review for BLA and EMA Accepts MAA for Apitegromab as a Treatment for SMA
-
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
-
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
-
Scholar Rock Holding Corp. (SRRK) announces employee inducement grants
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
-
Scholar Rock Holding Corp. (SRRK) Submits BLA to the U.S. FDA for Apitegromab as a Treatment for Patients with SMA
-
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
-
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Holding Corp. (SRRK) Highlights 2025 Strategic Priorities
-
Scholar Rock Highlights 2025 Strategic Priorities
